ReviewCurrent opinion in microbiology2024
Innate immune response to Candida auris.
Review in Current opinion in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence, mortality, and comorbidities of patients with diabetes mellitus and proven Candida auris emerging infection: a systematic review & meta-analysis.BMC infectious diseases · 2026Pooled it
- Pathogenicity and virulence ofVirulence · 2026Review
- The Immunomodulatory Effects of Mannan on the Fungicidal Activity of Macrophages AgainstMicroorganisms · 2026Article
- Morphotype-specific susceptibility toMicrobiology spectrum · 2026Article
- Article
- Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026Article
- Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Review
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections.Virulence · 2025Review
- The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.International journal of molecular sciences · 2025Review
- Clove Oil-Based Nanoemulsion Containing Amphotericin B as a Therapeutic Approach to Combat Fungal Infections.Pharmaceutics · 2025Article
- Tolerance and heteroresistance to echinocandins inmSphere · 2025Review
- Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance.Microorganisms · 2025Review
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Candida auris, a newly emergent fungal species, has been spreading in health care systems and causing life-threatening infections. Intact innate immunity is essential for protection against many invasive fungal infections, including candidiasis. Here, we highlight recent studies exploring immune interactions with C. auris, including investigations using animal models and ex vivo immune cells. We summarize innate immune studies comparing C. auris and the common fungal pathogen Candida albicans. We also discuss how structures of the C. auris cell wall influence immune recognition, the role of soluble host factors in immune recognition, and areas of future study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.